DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vintafolide
Vintafolide
List Item Withdrawal Assessment Report for Folcepri
ESMO 2014 Scientific Meeting Report
545 © American Association of Pharmaceutical Scientists 2019 P. V
Esmo – Missed Target Leaves Endocyte Clutching at Straws
(Ec145) and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) in Combination Versus Pld in Patients with Platinum-Resistant Ovarian Cancer
Access to Cancer Medicines in Australia
Annexes to the Annual Report of the European Medicines Agency 2014
Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Folate Receptor: a Potential Target in Ovarian Cancer
Orphan Drug Designation List
WO2020264398A1.Pdf
Updates in Cancer for Clinicians
Updates in Cancer for Clinicians
(12) United States Patent (10) Patent No.: US 9,676,746 B2 Decrescenzo Et Al
CYTOTOXICITY of Se-LABELED ANTIBODIES and SELENOFOLATE AGAINST TRIPLE NEGATIVE BREAST CANCER CELL LINES MDA-MB-231 and MDA-MB-468
Advanced Epithelial Ovarian Cancer: from Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are We Now?
Endocyte's Good News Double Hits the Target with Investors
Top View
Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs
NDO Home | Contact | Register for NDO Access
Download Report
Targeting Folate Receptor Alpha for Cancer Treatment
(With Pegylated Liposomal Doxorubicin): Draft Scope
Phase I/II Clinical Trial of the Targeted Chemotherapeutic Drug, Folate-Tubulysin, in Dogs with Naturally-Occurring Invasive Urothelial Carcinoma
Orphan Drug Designation List
Bevacizumab in Combination with Gemcitabine and Carboplatin for Treating the First Recurrence of Platinum-Sensitive Advanced Ovarian Cancer
WO 2018/183580 Al 04 October 2018 (04.10.2018) W !P O PCT
Vintafolide—Targeting the Folate Receptor with a Cytotoxic Offers Hope
Pre-Clinical Evaluation of EC1456, a Folate-Tubulysin Anti-Cancer Therapeutic Received: 13 March 2018 Joseph A
Vintage Filings
Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-To-Bedside Journey
Structural Characterization and Therapeutic Utility of the Proton-Coupled Folate Transporter
Targeted Treatment of Folate Receptor-Positive Platinum-Resistant Ovarian Cancer and Companion Diagnostics, with Specific Focus on Vintafolide and Etarfolatide
WO 2016/123581 Al 4 August 2016 (04.08.2016) P O P C T
Folate Receptor-Positive Gynecological Cancer Cells: in Vitro and in Vivo Characterization
Pdf/2009-10/Firmagon - Ct-6725.Pdf 58
WHO Drug Information Vol
List Item Withdrawal Assessment Report for Vynfinit (PDF/2.12
Imaging the Folate Receptor on Cancer Cells with 99Mtc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging
Design of Targeted Photosensitizer-Conjugates Towards
Oncology Drugs in the Pipeline
Tumor-Targeted Drug Conjugates As an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
| Hao Wanata Ut Til En Una Ten Minut
Randomized Phase III Trial Comparing
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Narrative Review of Novel Chemotherapeutic Agents in Management of Ovarian Cancer
Final Scope PDF 242 KB
Gynecological Cancer Update
Inula Species
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
Ep 3348266 A1
Endocyte, Inc. 2016 Annual Report
Target Based Design and Synthesis of Fused Pyrimidines in the Potential Treatment of Cancer and Opportunistic Infection Khushbu Shah
Ovarian Cancer Relapse from the Latest Scientific Evidence to the Best
ATC Code Title
1078-0432.CCR-17-3457.Full.Pdf
Patient Selection and Targeted Treatment in the Management of Platinum-Resistant Ovarian Cancer
Translating the Molecular Complexity of Ovarian Cancer Into Treatment Advances
Final Scope PDF 214 KB